Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 34

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 34
---
 equipment and other relevant laboratory safety topics. We also extend this training to office staff and others who support our work in the labs. We have also established a health and safety committee to oversee the working conditions in our laboratory environment and conduct regular safety inspections.

Ethics and Compliance

Our Code of Business Conduct and Ethics outlines our commitment to ethical business practices and applies to all of our employees, officers and directors. Annual training on our Code of Business Conduct and Ethics is provided to all employees.

Code of Business Conduct and Ethics

Our board of directors has adopted the Repare Therapeutics Inc. Code of Business Conduct and Ethics that applies to all officers, directors and employees. This includes our principal executive officer, principal financial officer and principal accounting officer or controller or persons performing similar functions. The nominating and corporate governance committee is responsible for overseeing the Code of Business Conduct and Ethics and must approve any waivers of the Code of Business Conduct and Ethics for our employees, executive officers and directors. The Code of Business Conduct and Ethics is available on our website at ir.reparerx.com/corporate-governance/documents-and-charters. If we make any substantive amendments to the Code of Business Conduct and Ethics or grant any waiver from a provision of the Code of Business Conduct and Ethics to the principal executive officer, principal financial officer and principal accounting officer or controller or persons performing similar functions, we will promptly disclose the nature of the amendment or waiver on our website.

In accordance with the QBCA, directors and officers must disclose the nature and value of any interest he or she has in a contract or transaction, whether made or proposed (including related negotiations), to which we are a party. Such “interest” means any financial stake in a contract or transaction that may reasonably be considered likely to influence decision-making. Such disclosure is also required for any contract of transaction to which we are a party and (i) an associate of the director or officer; (ii) a group of which the director or officer is a director or officer; or (iii) a group in which the director or officer or an associate of the director or officer has an interest, whether or not such contract or transaction requires approval by our board of directors. Subject to certain limited exceptions under the QBCA, no director may vote on any resolution to approve, amend or terminate a contract or transaction which is subject to such disclosure requirement.**

<div align='center'>23</div>

Insider Trading Policy Our board of directors has adoptedthe Repare Therapeutics Inc. Insider Trading Policy (the “